Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, LTD. (NASDAQ:KMTS), disposed of 15,000 common shares of the company on March 17, 2026, in a transaction that produced about $304,123 in proceeds.
The shares were sold at a weighted average price of $20.2749, with execution prices spanning from $20.00 to $20.7709. At the time of reporting, Kestra Medical’s market price stood at $19.56, representing a 26% decline so far this year.
Following the sale, Webster retains direct ownership of 364,786 common shares. Kestra Medical Technologies, LTD. has a reported market capitalization of $1.14 billion. The sale was completed under a pre-arranged Rule 10b5-1 trading plan that was adopted on September 29, 2025.
Separately, Kestra Medical released its fiscal third-quarter results that contained a mix of outcomes across profitability and top-line measures. The company reported an actual diluted earnings per share of -$0.61, missing the consensus forecast of -$0.42. The gap between actual and forecasted EPS equates to a 45.24% shortfall relative to the expectation provided.
On the revenue front, Kestra Medical posted sales that were nearly 7% higher than expectations. The company also highlighted strong gross margin performance and an adjusted EBITDA loss that came in better than anticipated.
Market-facing analysis cited in company coverage shows a divergence in investor and analyst reaction. Piper Sandler has reiterated an Overweight rating on Kestra Medical and maintained a $30.00 price target. The firm’s commentary points to positive investor sentiment, which it associates with the company’s robust revenue growth and favorable product developments despite the earnings shortfall.
Additional commentary from data services notes that InvestingPro’s analysis flags KMTS as appearing overvalued at current levels. InvestingPro subscribers are reported to have access to five additional exclusive tips and expanded financial metrics for KMTS.
The combination of an insider sale under a predetermined trading plan, a notable EPS miss alongside a revenue beat, and an analyst-maintained Overweight rating frames a nuanced picture for Kestra Medical as market participants process the latest operational results and ownership activity.
Summary
- Kestra Medical CEO Brian Webster sold 15,000 shares on March 17, 2026, for approximately $304,123 under a Rule 10b5-1 plan.
- Transaction prices ranged from $20.00 to $20.7709 with a weighted average of $20.2749; the stock trades at $19.56, down 26% YTD.
- Kestra reported Q3 EPS of -$0.61 versus a -$0.42 forecast, while revenue exceeded expectations by nearly 7%.
Key points
- Insider transaction: The CEO executed a sale of common shares through a pre-arranged 10b5-1 plan, reducing direct holdings to 364,786 shares.
- Mixed earnings print: EPS missed consensus by a material margin while revenue outperformed estimates, and margin and adjusted EBITDA indicators were noted as resilient.
- Analyst stance: Piper Sandler retains an Overweight rating and a $30.00 target; InvestingPro flags the stock as appearing overvalued at current levels.
Risks and uncertainties
- Earnings risk - The reported EPS of -$0.61 missed the -$0.42 forecast by 45.24%, indicating near-term profitability challenges that affect investor perception in the healthcare and medical device sectors.
- Valuation concern - InvestingPro’s assessment that the stock appears overvalued introduces uncertainty for equity investors evaluating KMTS relative to its market capitalization of $1.14 billion.
- Market performance - The share price has declined to $19.56, down 26% year-to-date, which may influence trading liquidity and investor appetite in the healthcare-equipment segment.
Note: The article reports the transaction details, company results, analyst rating, and third-party valuation commentary as provided; it does not infer causes beyond the supplied information.